Endocarditis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major endocarditis markets are expected to exhibit a CAGR of 4.22% during 2024-2034.
The endocarditis market has been comprehensively analyzed in IMARC's new report titled "Endocarditis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Endocarditis refers to a medical condition characterized by the inflammation and infection of the inner lining of the heart chambers and heart valves. The symptoms of the ailment can vary depending on the severity of the infection and the individual affected. Some of the common indications include fever, chills, fatigue, weakness, muscle and joint pain, shortness of breath, new or changing heart murmurs, swelling in the legs, feet, or abdomen, skin rashes or small spots on the skin, etc. In severe cases, various complications, such as heart failure, stroke, sepsis, etc., can occur. The diagnosis of endocarditis usually involves a combination of medical history, physical exam, and laboratory tests. Numerous blood tests, such as an elevated white blood cell count or increased levels of C-reactive protein, are conducted to look for signs of infection. Additionally, blood cultures are used to identify the specific microorganisms causing the infection. Several other imaging procedures, including a chest X-ray or CT scan, may also be performed to evaluate the extent of the condition and detect any complications.
The increasing cases of invasive medical procedures, such as surgery or catheterization, that cause bacteria to enter the bloodstream and attach to damaged or abnormal heart valves are primarily driving the endocarditis market. Furthermore, the rising prevalence of various associated risk factors, including skin infections, intravenous drug use, underlying heart conditions, etc., is also propelling the market growth. Apart from this, the inflating demand for intravenous antibiotics on account of their several benefits, such as rapid absorption, reduced risk of side effects, effectiveness against resistant strains, etc., is acting as another significant growth-inducing factor. Additionally, the introduction of antibiotic stewardship programs in various hospitals and clinics to help prevent antibiotic resistance and improve the efficacy of endocarditis treatment is creating a positive outlook for the market. Moreover, the rising usage of transesophageal echocardiography (TEE) for identifying signs of endocarditis, such as valve damage or vegetation (clumps of infected material), that may not be visible with other imaging techniques, is expected to drive the endocarditis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the endocarditis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for endocarditis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the endocarditis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the endocarditis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the endocarditis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current endocarditis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the endocarditis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the endocarditis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the endocarditis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of endocarditis across the seven major markets?
What is the number of prevalent cases (2018-2034) of endocarditis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of endocarditis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with endocarditis across the seven major markets?
What is the size of the endocarditis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of endocarditis?
What will be the growth rate of patients across the seven major markets?
Endocarditis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for endocarditis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the endocarditis market?
What are the key regulatory events related to the endocarditis market?
What is the structure of clinical trial landscape by status related to the endocarditis market?
What is the structure of clinical trial landscape by phase related to the endocarditis market?
What is the structure of clinical trial landscape by route of administration related to the endocarditis market?
The endocarditis market has been comprehensively analyzed in IMARC's new report titled "Endocarditis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Endocarditis refers to a medical condition characterized by the inflammation and infection of the inner lining of the heart chambers and heart valves. The symptoms of the ailment can vary depending on the severity of the infection and the individual affected. Some of the common indications include fever, chills, fatigue, weakness, muscle and joint pain, shortness of breath, new or changing heart murmurs, swelling in the legs, feet, or abdomen, skin rashes or small spots on the skin, etc. In severe cases, various complications, such as heart failure, stroke, sepsis, etc., can occur. The diagnosis of endocarditis usually involves a combination of medical history, physical exam, and laboratory tests. Numerous blood tests, such as an elevated white blood cell count or increased levels of C-reactive protein, are conducted to look for signs of infection. Additionally, blood cultures are used to identify the specific microorganisms causing the infection. Several other imaging procedures, including a chest X-ray or CT scan, may also be performed to evaluate the extent of the condition and detect any complications.
The increasing cases of invasive medical procedures, such as surgery or catheterization, that cause bacteria to enter the bloodstream and attach to damaged or abnormal heart valves are primarily driving the endocarditis market. Furthermore, the rising prevalence of various associated risk factors, including skin infections, intravenous drug use, underlying heart conditions, etc., is also propelling the market growth. Apart from this, the inflating demand for intravenous antibiotics on account of their several benefits, such as rapid absorption, reduced risk of side effects, effectiveness against resistant strains, etc., is acting as another significant growth-inducing factor. Additionally, the introduction of antibiotic stewardship programs in various hospitals and clinics to help prevent antibiotic resistance and improve the efficacy of endocarditis treatment is creating a positive outlook for the market. Moreover, the rising usage of transesophageal echocardiography (TEE) for identifying signs of endocarditis, such as valve damage or vegetation (clumps of infected material), that may not be visible with other imaging techniques, is expected to drive the endocarditis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the endocarditis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for endocarditis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the endocarditis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the endocarditis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the endocarditis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current endocarditis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the endocarditis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the endocarditis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the endocarditis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of endocarditis across the seven major markets?
What is the number of prevalent cases (2018-2034) of endocarditis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of endocarditis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with endocarditis across the seven major markets?
What is the size of the endocarditis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of endocarditis?
What will be the growth rate of patients across the seven major markets?
Endocarditis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for endocarditis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the endocarditis market?
What are the key regulatory events related to the endocarditis market?
What is the structure of clinical trial landscape by status related to the endocarditis market?
What is the structure of clinical trial landscape by phase related to the endocarditis market?
What is the structure of clinical trial landscape by route of administration related to the endocarditis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ENDOCARDITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ENDOCARDITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ENDOCARDITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ENDOCARDITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ENDOCARDITIS - UNMET NEEDS
10 ENDOCARDITIS - KEY ENDPOINTS OF TREATMENT
11 ENDOCARDITIS - MARKETED PRODUCTS
11.1 List of Endocarditis Marketed Drugs Across the Top 7 Markets
11.1.1 Cubicin (Daptomycin intravenous) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ENDOCARDITIS - PIPELINE DRUGS
12.1 List of Endocarditis Pipeline Drugs Across the Top 7 Markets
12.1.1 CF 301 - ContraFect
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ENDOCARDITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ENDOCARDITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ENDOCARDITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Endocarditis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Endocarditis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Endocarditis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Endocarditis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Endocarditis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Endocarditis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Endocarditis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Endocarditis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Endocarditis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Endocarditis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Endocarditis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Endocarditis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Endocarditis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Endocarditis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Endocarditis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Endocarditis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Endocarditis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Endocarditis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Endocarditis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Endocarditis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Endocarditis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Endocarditis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Endocarditis - Access and Reimbursement Overview
16 ENDOCARDITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ENDOCARDITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ENDOCARDITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ENDOCARDITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ENDOCARDITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ENDOCARDITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ENDOCARDITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ENDOCARDITIS - UNMET NEEDS
10 ENDOCARDITIS - KEY ENDPOINTS OF TREATMENT
11 ENDOCARDITIS - MARKETED PRODUCTS
11.1 List of Endocarditis Marketed Drugs Across the Top 7 Markets
11.1.1 Cubicin (Daptomycin intravenous) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ENDOCARDITIS - PIPELINE DRUGS
12.1 List of Endocarditis Pipeline Drugs Across the Top 7 Markets
12.1.1 CF 301 - ContraFect
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ENDOCARDITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ENDOCARDITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ENDOCARDITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Endocarditis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Endocarditis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Endocarditis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Endocarditis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Endocarditis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Endocarditis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Endocarditis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Endocarditis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Endocarditis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Endocarditis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Endocarditis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Endocarditis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Endocarditis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Endocarditis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Endocarditis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Endocarditis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Endocarditis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Endocarditis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Endocarditis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Endocarditis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Endocarditis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Endocarditis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Endocarditis - Access and Reimbursement Overview
16 ENDOCARDITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ENDOCARDITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ENDOCARDITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
